PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
302.55%
Some net income increase while VET is negative at -9.97%. John Neff would see a short-term edge over the struggling competitor.
191.13%
D&A growth well above VET's 11.21%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.94%
Negative yoy working capital usage while VET is 123.95%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.94%
Negative yoy usage while VET is 123.95%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-410.39%
Negative yoy while VET is 4371.43%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
314.66%
Operating cash flow growth 1.25-1.5x VET's 247.33%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
-219.89%
Both yoy lines negative, with VET at -2061.68%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-4400.93%
Negative yoy acquisition while VET stands at 100.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
129.98%
We have some outflow growth while VET is negative at -26.07%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-216.10%
Both yoy lines negative, with VET at -55.97%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
218.27%
We slightly raise equity while VET is negative at -83.35%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.